For initial treatment...
Adding RITUXAN to Fludarabine and Cyclophosphamide (FC) Chemotherapy May Improve CLL Treatment Response
RITUXAN is used along with FC chemotherapy as an initial treatment for CLL. In fact, in a large clinical study (called CLL8), 86% of patients who received RITUXAN plus FC chemotherapy went into either partial or complete remission for a period of time.
Keep in mind: Remission can be partial or complete. Partial remission means the cancer is significantly improved, but evidence of the cancer remains. Complete remission means all evidence of the cancer is gone for a period of time.
Adding RITUXAN to FC chemotherapy meant patients experienced an average of 3.3 years without their cancer advancing.
The CLL8 study
About the patients
- Average age: 61
- 408 patients received RITUXAN plus FC chemotherapy
- 409 patients received FC chemotherapy alone
- These previously untreated patients were in the later stages of disease
- The patients had few medical conditions in addition to CLL and were generally healthy enough to receive treatment
Important treatment considerations
- Remember that results are different for different people. Some results from this study suggest that patients 70 years or older may not benefit from the addition of RITUXAN to FC chemotherapy. Please talk to your doctor about the potential benefits and risks for RITUXAN plus FC chemotherapy
- Most patients treated with RITUXAN plus FC chemotherapy experienced at least one serious side effect
- In previously untreated patients, serious side effects included infusion reactions, low white blood cells, fever, low red blood cells, low platelets, and infections
- Serious side effects were reported more often in patients over 70 years of age who received RITUXAN plus FC chemotherapy (compared to patients younger than 70)
This information does not take the place of talking with your doctor. Discuss with your doctor any questions you have about your medical condition or your treatment.